JS

Jaya Shukla

Active Director Director DIN 11563717
DIN 11563717 First appointment Feb 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Jaya Shukla

Data last updated:

Jaya Shukla is a Director at Arveg Lifesciences Private Limited (since 2026). The company operates in Pharma.

DIN 11563717
Primary Designation Director
Industry Pharma
First Appointment 22 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Arveg Lifesciences Private Limited U21000GJ2026PTC173996
Director22 Feb 20262026Active

Board colleagues of Jaya Shukla

NameDINCompanyDesignation
Gunja Saxena11563716Arveg Lifesciences Private LimitedDirector

Directorship timeline

Open interactive timeline →
Arveg Lifesciences Private Limited
Premium access

Shareholding and investment profile for Jaya Shukla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jaya Shukla

Jaya Shukla currently holds 1 directorship: Arveg Lifesciences Private Limited (Director, since 22 Feb 2026).

Jaya Shukla was first appointed on 22 Feb 2026 as Director at Arveg Lifesciences Private Limited.

The current boards of Jaya Shukla's companies include Gunja Saxena (Arveg Lifesciences Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available